Is carotid angioplasty and stenting more cost effective than carotid endarterectomy?  by Kilaru, Sashi et al.
Is carotid angioplasty and stenting more cost
effective than carotid endarterectomy?
Sashi Kilaru, MD,a Peter Korn, MD,a Karthikeshwar Kasirajan, MD,b Thomas Y. Lee, MD,a
Frederick P. Beavers, MD,a Ross T. Lyon, MD,a Harry L. Bush, MD,a and K. Craig Kent, MD,a
New York, NY; and Albuquerque, NM
Objective: Carotid angioplasty and stenting (CAS) has been advocated as a minimally invasive and inexpensive alternative
to carotid endarterectomy (CEA). However, a precise comparative analysis of the immediate and long-term costs
associated with these two procedures has not been performed. To accomplish this, a Markov decision analysis model was
created to evaluate the relative cost effectiveness of these two interventions.
Methods: Procedural morbidity/mortality rate for CEA and costs (not charges) were derived from a retrospective review
of consecutive patients treated at New York Presbyterian Hospital/Cornell (n 447). Data for CAS were obtained from
the literature. We incorporated into this model both the immediate procedural costs and the long-term cost of
morbidities, such as stroke (major stroke in the first year  $52,019; in subsequent years  $27,336/y; minor stroke 
$9419). We determined long-term survival rate in quality-adjusted life years and lifetime costs for a hypothetic cohort of
70-year-old patients undergoing either CEA or CAS. Our measure of outcome was the cost-effectiveness ratio.
Results: The immediate procedural costs of CEA and CAS were $7871 and $10,133 respectively. We assumed major plus
minor stroke rates for CEA and CAS of 0.9% and 5%, respectively. We assumed a 30-day mortality rate of 0% for CEA and
1.2% for CAS. In our base case analysis, CEA was cost saving (lifetime savings  $7017/patient; increase in
quality-adjusted life years saved  0.16). Sensitivity analysis revealed major stroke and death rates as the major
contributors to this differential in cost effectiveness. Procedural costs were less important, and minor stroke rates were
least important. CAS became cost effective only if its major stroke and mortality rates were made equivalent to those of
CEA.
Conclusion: CEA is cost saving compared with CAS. This is related to the higher rate of stroke with CAS and the high cost
of stents and protection devices. To be economically competitive, the mortality and major stroke rates of CAS must be at
least equivalent if not less than those of CEA. (J Vasc Surg 2003;37:331-9.)
On the basis of the results of numerous published
randomized trials, carotid endarterectomy (CEA) has been
established as the “gold standard” in the treatment of
stenotic lesions of the extracranial carotid arteries. How-
ever, in recent years, carotid angioplasty and stenting
(CAS) has emerged as a new innovative and less invasive
approach to the treatment of carotid artery stenosis.
Reported advantages of CAS include decreased cost, a
shorter recovery period, diminished morbidity, and greater
patient appeal.1-4 Because of the limitations in healthcare
resources and a plethora of expensive technology, enthusi-
asm for any new and potentially beneficial intervention
must be tempered with a consideration of its cost. Policy-
makers and insurers must now consider not only whether
new strategies for the treatment of patients improve quality
of life but also whether these same practices are cost effec-
tive within a range deemed acceptable to society.
Decision analysis models that use morbidity, mortality,
and cost as endpoints are powerful tools that can be used to
validate the utility of a medical intervention. A critical
element of decision analysis is its ability to assess both the
immediate costs and outcome of an intervention and the
long-term costs and sequelae. Although there have been
previous attempts to evaluate the cost effectiveness of CAS
versus CEA, in the studies published thus far, only costs
associated with the initial hospitalization have been consid-
ered.2,5 A formal cost-effectiveness analysis has not been
performed.
To this end, we have developed a comprehensive
Markov model that incorporates not only the cost incurred
during the initial hospitalization but also the costs of com-
plications, subsequent interventions, and long-term out-
comes of patients undergoing either CAS or CEA. The goal
of this analysis was to determine whether CAS is a cost
effective alternative to CEA in the treatment of carotid
stenosis.
MATERIALS AND METHODS
Decision analysis model
We have developed a decision analysis model that re-
flects the possible clinical outcomes and costs associated
with a hypothetic 70-year-old cohort of patients with ca-
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rotid artery stenosis. Patients were randomly assigned to
undergo either CEA or CAS (Fig 1). Selection criteria for
CEA and CAS were carotid stenoses greater than 70%
(symptomatic) or 80% (asymptomatic). Treatment with
either strategy was associated with numerous possible 30-
day outcomes, including perfect health, minor or major
stroke (as defined in the North American Symptomatic
Carotid Endarterectomy Trial), or death. The definition of
major and minor stroke was on the basis of the Rankin
score. These various outcomes formed the “branches” of a
decision tree (Fig 1). A probability of occurrence and cost
was assigned to each branch. With a computerized Markov
decision analysis model (DATA 3.5.4, Treeage software,
Inc, Williamstown, Mass; 1998), all of the possible clinical
events and outcomes that occurred in both groups of
patients were tracked and compared. The Markov model
allows these patients to be followed until death. All the
costs were converted to 1997 US dollars with the medical
care component of the Consumer Price Index for All Urban
Consumers. In accordance with standard principles of eco-
nomic analysis, the costs and life expectancies were dis-
counted at 3% per year to reflect the greater value of current
dollars and life years as compared with that of the future.6
Our measure of outcome was the cost effectiveness ratio,
which is defined as the difference in lifetime costs divided by
the difference in life expectancy incurred by two interven-
tions. Interventions can be discarded or adopted on the
basis of their costs and effectiveness (Table I).
In the initial (base case) analysis, probabilities, and costs
were derived from patients undergoing CEA at New York
Presbyterian Hospital and the New York Presbyterian Hos-
pital cost accounting system. The quality-adjustment fac-
tors were derived from the literature. With the realization
that probabilities and costs may vary between surgeons and
institutions, in sensitivity analysis, we systematically varied
these assumptions through a wide plausible range and
tested the effect of these variations on the base case conclu-
sions. Because most widely accepted medical interventions
have cost-effectiveness ratios of less than $60,000 (Table
II), we considered this value to be the threshold for our
sensitivity analysis.7
Base case assumptions
Probabilities. Carotid endarterectomy data were ob-
tained from a retrospective review of 447 CEAs performed
at New York Presbyterian Hospital from 1997 to 2001.
The probabilities for CAS including complications were
obtained from recent reports from the literature.
The 30-day probability of stroke and death for patients
undergoing CEA was 0.9% (major stroke, 0.45%; minor
stroke, 0.45%; and death, 0%). We assumed for CAS a
30-day probability of stroke and death of 6.2% (major
stroke, 1.8%; minor stroke, 3.2%; and death, 1.2%). Values
for CAS were derived from an average of data obtained
from recent peer reviewed published reports3,5,8-10 (Table
III). The incidence rate of myocardial infarction in the CEA
Table I. Analysis of cost effectiveness of new strategy
(CAS) versus alternative (CEA)
Costs Effectiveness Conclusions
1 2 Do not adopt
1 1 Determine CER; adopt
if  $60,000
2 1 Adopt
CER, Cost-effectiveness ratio.
Fig 1. Simplified Markov decision analysis model. Hypothetic 70-year-old cohort of patients with carotid artery
stenosis was randomly assigned to undergo either CEA or CAS. Treatment with either strategy was associated with
numerous possible 30-day outcomes, including perfect health, minor and major stroke, or death.
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group was 1.1%. None of the patients with infarction were
symptomatic, and all cases were detected through perfunc-
tory performance of enzyme analysis or electrocardiogram.
We assumed the rate of myocardial infarction was 0.8% in
the CAS group on the basis of a review of the available
literature.11 Reexploration for a neck hematoma occurred
in only one patient in the CEA group (0.2%). We assumed
the incidence rate of groin hematoma necessitating inter-
vention to be 0.8% in the CAS group on the basis of data
from several reports.12 We assumed for CAS the rate of
restenosis necessitating reintervention to be 3%13 and that
for CEA to be 1%. We assumed that all reinterventions for
restenosis were treated with carotid stenting. Eight cranial
nerve injuries (1.7%) were noted in the CEA group, all of
which were transient (Table IV).
Costs. Procedural costs. We determined procedural
costs with evaluation first of resource utilization for each
procedure and then multiplication of total utilization by
unit cost (Table V). As an example, the average operating
room cost per patient for CEA was determined by multi-
plying an average operating room time (time the room was
occupied) of 228 minutes by a calculated operating room
cost of $1372 per hour for the first hour and $230 for each
additional half hour. Resource utilization for CAS was
obtained from the literature. However, the cost of re-
sources for CAS, such as the angiography suite, was also
obtained from the cost accounting system at New York
Presbyterian Hospital. Professional fees were derived from
the Medicare reimbursement for the year 2002 for the
appropriate Current Procedural Terminology codes. The
procedural cost of CEA, including anesthesia, was esti-
mated at $7871 on the basis of the last 447 procedures
performed at this institution. The average cost of CAS was
calculated to be $10,133. The average time for CAS was
estimated to be 90 minutes.14-16 We identified the sheaths,
catheters, guidewires, and balloons that are used in a typical
procedure and determined the costs for these various items
by averaging prices from multiple vendors (Table V). We
used the cost of an angiography suite at our institution of
$1100 for the first hour and $300 for each subsequent half
hour. The professional fee for the interventionalist was
calculated to be $1242. Additional costs assigned to CAS
included the costs of a stent, a cerebral protection device,
and an arterial closure device. The average length of stay for
patients for CAS was assumed to be 1.9 days and included
additional length of stay related to complications.15,16 We
assumed that 15% of patients would spend at least 24 hours
in the intensive care unit for blood pressure monitoring and
that the remaining 85% would be monitored in a telemetry
unit before discharge (cost of telemetry unit bed/day,
$1140)
Cost of morbidity. Direct costs of stroke were esti-
mated from the literature. With these assumptions, we
derived a cost of $52,019 for the first year after a major
stroke and an annual cost of $27,336 for subsequent years.
We used $9419 as the average cost for patients with minor
strokes. For a clinically significant myocardial infarction, we
estimated a cost of $11,000 for the first year and $2800 for
each year thereafter.12,13 We assumed 120 minutes of
operative time for wound exploration for hematomas at a
cost of $1700 (Table IV). In general, postoperative com-
plications that were not associated with long-term sequelae,
such as small hematomas, produced an increase in length of
stay but had no economic impact.
Quality adjustment. The outcome most often used in
cost-effectiveness analysis is quality-adjusted life expect-
ancy, which is measured in quality-adjusted life years. Be-
cause the quality of life associated with some health states
may be less desirable than those of others, life expectancy is
adjusted for quality of life. The quality-adjustment factor
may range from 0 (death) to 1 (perfect health). We used a
quality-adjustment factor of 0.40 for patients who survived
a major stroke.17 Patients who had a minor stroke were
assigned a disutility of 0.25 years, meaning that 3 months
were subtracted from their overall quality-adjusted life ex-
pectancy. We assumed a quality-adjustment factor of 0.88
for myocardial infarction.18 Cranial nerve injuries were
assigned a disutility of 0.15 years. We assumed a disutility of
2 days for CAS and 2 weeks for CEA.
RESULTS
Base case analysis. With our base case assumptions,
we calculated the life expectancy and lifetime costs for a
hypothetic cohort of patients undergoing either CAS or
CEA. The survival of patients after CAS, calculated in
quality-adjusted life years, was 8.20 and after CEA was
8.36. Thus, patients undergoing CEA lived 0.16 years
longer than those undergoing CAS. The lifetime costs for
CAS and CEA were $35,789 and $28,772, respectively.
Thus, CAS was $7017 more costly (over a patient’s life-
time) than CEA. Because CEA resulted in a greater life
expectancy and cost less than CAS, we considered CEA to
be cost saving. In other words, CEA was the optimal
procedure both in terms of cost and life expectancy.
Sensitivity analyses. With the realization that the
variables that we chose for our base case analysis may vary
Table II. Cost-effectiveness ratios for common medical
practices
Medical intervention Cost-effectiveness ratio ($/QALY)
CEA for patients who are
symptomatic
4600
CABG for left main disease 9500
Endovascular repair of 5-cm
AAA
22,826
Hemodialysis for ESRD 54,400
CEA for patients who are
asymptomatic
58,600
Routine cell saver device for
elective AAA
120,800
Orthotopic liver transplant for
hepatocellular cancer
136,900
QALY, Quality-adjusted life year; CABG, coronary artery bypass grafting;
AAA, abdominal aortic aneurysm; ESRD, end-stage renal disease.
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between institutions and physicians practices, we per-
formed sensitivity analyses to evaluate the effect of wide
variations in costs and event rates on the outcome of our
analysis (Table VI). Our goal was to determine which of the
variables had the greatest impact on cost effectiveness.
In our base case analysis, we assigned a mortality rate of
0% for CEA and 1.2% for CAS. Even if the mortality rate for
CAS was decreased to that of CEA, CEA still remained cost
saving. We assigned a perioperative risk of major stroke of
0.45% for CEA and 1.8% for CAS. If the rate of major
stroke for CAS decreased to that of CEA (0.45%), CEA
remained cost saving. We assigned a perioperative risk of
minor stroke of 0.45% for CEA and 3.2% with CAS. Once
again, if the rate of minor stroke for CAS was reduced to
that of CEA, CEA remained cost savings. And finally, for
our base case analysis, we used a procedural cost of $7871
for CEA and $10,133 for CAS. If the procedural cost of
CAS was reduced to that of CEA, CEA remained cost
saving. Thus, in one-way sensitivity analyses, CEA re-
mained cost saving despite the establishment of equivalence
for CEA and CAS of any individual variable (Table VI).
With the advent of lower profile stents and improved
cerebral protection, the combined morbidity and mortality
associated with CAS could potentially approach that of
CEA. Thus, in our next analysis, we simultaneously de-
creased the major and minor stroke rates and the mortality
rate of CAS to levels equivalent to that of CEA. This
resulted in a cost-effectiveness ratio for CAS of $68,800, a
value that approaches the range of accepted medical inter-
ventions (we choose $60,000 as our threshold).
With the assumption of equivalent major mortality and
morbidity for the two procedures, we then searched for
additional variables that might enhance the cost effective-
ness of CAS. Factors that appeared to be important were
the procedural costs of CAS and the disutility, or days of
incapacitation, related to the two procedures. Regarding
the latter, in our base case analysis, we assumed that CAS
would produce 2 days of incapacitation or the loss of 2 days
of life from the overall life expectancy of patients undergo-
ing this procedure. We assumed that CEA would result in
14 days of incapacitation, or the loss of 14 days of life from
patients undergoing CEA. Again, assuming equivalent
morbidity and mortality for the two procedures, we varied
the disutility assigned to CEA. If the disutility for CEA was
increased from 14 days to 21 days, CAS then became
extremely cost effective with a cost-effective ratio of
$39,315. Thus, if equipoise can be achieved between CEA
and CAS with regard to mortality and morbidity and one
assumes a disutility for surgery of 3 weeks, CAS becomes
the preferred procedure in terms of cost effectiveness.
We next sought to determine the variables in our
model that had the most substantial effect on lifetime
Table III. Studies used for base case analysis for CAS
Author Dates
No. of
patients
No. of
arteries Study design Years of study
Diethrich8 1996 110 117 Nonrandomized prospective 1993-1995
Wholey3 1997 108 114 Nonrandomized prospective 1993-1995
Jordan5 1998 109 109 Retrospective 1994-1995
Henry9 1998 163 174 Nonrandomized prospective 1995-1998
Roubin10 2001 528 604 Nonrandomized prospective 1994-1999
Table IV. Value of variables chosen for base case analysis
Variables CEA CAS CEA and CAS
Probabilities
Mortality 0% 1.2%
Major stroke 0.45% 1.8%
Minor stroke 0.45% 3.2%
MI 1.1% 0.8%
Hematomas 2.68% 0.8%
Restenosis 1% 3%
Cranial nerve injuries 1.78% 0%
Costs
Hospitalization $7871 $10,133
Major stroke $52,019/27,336
Minor stroke $9419
Reoperation for hematoma $1700
Cranial nerve injury $9500 Assumed
Quality-adjustment factors
Stroke 0.40
MI 0.88
Cranial nerve injury 0.85
MI, Myocardial infarction.
JOURNAL OF VASCULAR SURGERY
February 2003334 Kilaru et al
costs and life expectancy. We first evaluated the effect of
variations in the rate of major and minor stroke on the
lifetime cost of CAS (Fig 2). We found that major strokes
had a profound impact on lifetime costs whereas minor
strokes had a negligible effect. We also determined which
variables had the most profound impact on life expect-
ancy after CAS (Fig 3). Not surprisingly, we found that
the major stroke rate and perioperative mortality rate had
the most significant impact on life expectancy. Minor
stroke again had minimal impact. These data show that
the cost effectiveness of CAS is critically dependent on
the major stroke rate and on procedural costs and mor-
tality. The rate of minor stroke was less important than
these other variables.
We varied the reintervention rates for CAS and CEA
(base case reintervention rate: CAS, 3%; CEA, 1%) in
sensitivity analysis and found little impact on the out-
come of our analysis. We also varied the age of the
hypothetic patient cohort from 50 through 90 years.
With the assumption that all other variables remained
constant, the cost effectiveness of CEA was further en-
hanced in patients who were less than 70 years of age.
However, CEA remained cost saving even in patients up to
90 years of age.
Table V. Cost breakdown for CEA and CAS
Unit cost
Utilization/patient Total cost/patient
CEA CAS CEA CAS
Operating room $1373/first h 228 min $2660
$230/each subsequent 30 min
Angio suite $1100/first h 90 min $1400
$300/each subsequent 30 min
EEG $430 1 $430
TCD $275 1 $275
Shunt $110 5% $5
Patch $310 1 $310
Vessel loops $2.80 5 $14
Sutures $5 5 $25
Endovascular equipment
Conray dye $168/100 mL 125 mL $210
Vessel puncture kit $28 1 $28
5F sheath $18 1 $18
260-cm 0.035 in glidewire $52 1 $52
Pig-tail catheter $18 1 $18
Power injector tubing $5 2 $10
VTK or head hunter or vertebral
catheter or angled glidewire
$20 1 $20
260-cm Amplatz $47 1 $47
BMW 0.014 in wire or choice floppy
or choice extra support
$105 1 $105
90-cm Shuttle sheath or 80-cm Raabe
sheath or H-1 guide sheath
$110 1 $110
5  2 Savvy balloon or 4  2 cross
sail balloon or 4  2 ranger balloon
$390 1 $390
Balloon insufflator $90 1 $90
Torque device $8 1 $8
8  4 Precise stent or Dynalink stent
or Precise taper stent
$1800 1 $1800
Percusurg embolic protection device
or Angiogaurd or EPI filter
$1600 1 $1600
Femoral puncture closure device:
Perclose or angioseal or vasoseal
$190 1 $190
Surgeon/interventionalist
reimbursement (Medicare-2002)
$1285 $1242
Anesthesia reimbursement $23/unit 26 units $600
Postoperative
ICU $1500/d 9% 9.8% $336 $225
Telemetry unit $1140/d 90.2% $1995
PACU $1100/d 6% $183
Ward $930/d 85% $2022
Hospitalization cost $2542 $2220
Plavix (75 mg/d for 4 wks) $150
Total costs $7871 $10,133
EEG, Electroencephalography; TCD, transcranial Doppler; VTK, VITEK; BMW, Balance Middleweight Universal guidewire; ICU, intensive care unit; PACU,
postanesthesia care unit.
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DISCUSSION
Two previous attempts have been made to define and
compare the costs associated with CEA and CAS.6,9 How-
ever, both analyses were limited to the costs associated with
the initial hospitalization. Moreover, in one of the two
studies, charges were evaluated rather than costs.5 To com-
pare the true cost effectiveness of CEA and CAS in the
management of carotid stenosis requires consideration of
both lifetime costs and effectiveness. To this end, we con-
structed a Markov decision analysis model in which the
strategies of CEA and CAS were compared. In our base case
analysis, we found that CAS was more expensive than CEA.
Moreover, CAS reduced rather than extended life expect-
ancy. In other words, CAS costs more and is less effective
than CEA. Consequently, a cost-effectiveness ratio could
not be determined. Thus, we concluded that CEA is cost
saving compared with CAS. In our initial analysis, we
compared the costs and outcomes for CEA at a single
institution with results reported in the literature for CAS.
In determining the outcomes for CAS, we averaged the
results of several modern studies performed by investigators
with substantial experience with this technique. It could be
argued that the outcomes of CEA that we used for this
model were more favorable than those reported by large
multicenter trials. However, the recent literature is replete
with single institution series of CEA touting rates of stroke
and death in the 0.5% to 2% range.19-21 Moreover, the data
that we report for CAS were also derived from single
institutional experiences. We do recognize that morbidity,
mortality, and costs will vary between surgeons and insti-
tutions. Moreover, the technology, expertise, and conse-
quently, the results associated with CAS may improve over
time. Accordingly, sensitivity analyses were performed to
determine the influence of these variables on our base case
conclusion. The immense benefit of a decision analysis
model is its flexibility. The assignment of any variable can
be changed, and the effect of this variation on outcome can
be calculated.
We first analyzed the cost of the initial hospitalization
for the two interventions. In our base case analysis, we
found the cost of the initial hospitalization to be approxi-
mately 25% higher for CAS ($10,133) versus CEA
($7871). Although many variables were incorporated into
this calculation, the most influential factors leading to this
differential in cost were the stent and the protection device.
The cost of a stent can range from $1400 to $1800, and the
cost of a protection device is similar. With other “minimally
invasive” vascular procedures, such as endovascular repair
of abdominal aortic aneurysm, the additional expense of
the device is offset, to some extent, by a decrease in the
length of hospital stay. However, a similar benefit does not
exist for CAS. The safety of an overnight stay for routine
CEA has been repeatedly established. Although procedural
times and length of stay may be modestly less with CAS, the
cost savings associated with these variations is minor com-
pared with the cost of a stent and protection device. For
example, decreasing the procedural time for CAS from 90
Fig 2. Impact of rate of major and minor stroke associated with CAS on lifetime costs of CAS. *Value assumed in base
case analysis.
Table VI. Range of variables tested in sensitivity analysis
Variable CEA base case CAS base case Range*
Mortality 0% 1.2% 0-5%
Major stroke 0.45% 1.8% 0-5%
Minor stroke 0.45% 3.2% 0-10%
MI 1.1% 0.8% 0-5%
Age (y) 70 70 50-90
Procedure costs $7689 $10,133 $5000-$15000
*Both CEA and CAS were varied over these ranges.
MI, Myocardial infarction.
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to 60 minutes (total room time) saves $230 per patient, a
small number relative to a cost of $3200 for the stent and
the protection device. It seems unlikely in the near future
that the procedural costs of CAS will diminish to any great
extent.
The cost associated with major morbidities is often
overlooked when comparing the cost effectiveness of two
interventions. The most prevalent morbidity associated
with either CAS or CEA is stroke. The expense to society of
a major stroke is substantial, as high as $160,000 per
patient over a period of 5 years. Varying the rate of major
stroke in sensitivity analyses had a substantial impact on
both life expectancy of patients and cost (Fig 2). Interest-
ingly, we found that varying the rate of minor stroke had
little effect on the outcome of this analysis. Most minor
strokes are transient, and the disutility from these events is
not substantial. Moreover, the cost associated with minor
strokes is relatively minor. This observation is important
because, in many series of CAS, most strokes are minor.
Thus, if rates of major stroke and death for CAS can be
brought into the range of CEA, from a cost-effective stand-
point, equipoise may be achieved.
The goal of the study was to create a model that
allowed determination of the relative cost effectiveness of
CEA and CAS. We believe that we have effectively accom-
plished this task in that our model includes all of the
relevant variables that need to be considered. The issue that
arises with any decision analysis model is the validity of the
values that are chosen for these variables. The outcomes for
CAS are still evolving. This may be true even for CEA.
Recently reported rates of stroke with CEA are more favor-
able than those reported 10 years ago in the North Amer-
ican Symptomatic Carotid Endarterectomy Trial. Realisti-
cally, it will be at least 5 years before comparative level I
data are available for both techniques. In the absence of
level one data, decision analysis techniques have been used
extensively to evaluate many new technologies. The onus is
on the authors of such models to make the best assump-
tions possible. Moreover, sensitivity analyses function as an
important tool to allow evaluation of the effect of a variety
of different clinical scenarios on the model’s outcome. We
were able to predict from this model, on the basis of
sensitivity analyses, that the major stroke and mortality of
CAS must approach that of CEA before there can be parity
in cost effectiveness. This conclusion is the thrust of the
manuscript and can be made regardless of the variables
chosen for the base case analysis.
Is it possible that the demand for CAS because of its
“minimally invasive” nature will overwhelm any consider-
ation of cost? There are in fact few rules regarding what
society is willing to pay for new medical interventions.
Patient demand can to a great extent drive the availability of
resources. Hospitals may offer patients cutting edge tech-
nology, despite a loss in revenue, so as to maintain domi-
nance in the treatment of a particular type of disease.
Moreover, Medicare and other insurers, related to patient
desire, may choose to reimburse carotid stenting even if the
costs are higher. However, with the plethora of new tech-
nology that is now available and limited healthcare re-
sources, it is safe to assume that cost will continue to play an
important role in such decisions.
When additional experience with CAS is gained, more
definitive data regarding costs and outcome can be applied
to this or similar models. However, this analysis suggests
that, to be economically competitive with CEA, CAS must
be performed with mortality and stroke rates that are less
than those of CEA. A true assessment of the cost effective-
ness of CAS will not be achievable until more definitive
long-term trials, such as the Carotid Revascularization
Endarterectomy Versus Stent Trial, have been completed.
Fig 3. Impact of variations in mortality and major and minor stroke rates associated with CAS on quality of life years
for CAS. *Value assumed in base case analysis. QALY, Quality-adjusted life year.
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DISCUSSION
Dr Richard M. Green (Rochester, NY). One could take the
approach that this is a very self-serving kind of analysis because you
are a surgeon and there are other technologies that we are embark-
ing on and they are going to cost more. So, what should we do,
abandon the technologies?
Dr Sashi Kilaru. I do not think that is the emphasis of the
paper. I think this paper looks at it at a societal level to see if in fact
it is cost effective. All we are trying to say at this time frame is that
it is not cost effective. With newer generation devices, it in fact may
become more cost effective and so it should be adopted. I think at
this point it should be done only in clinical trials in a fixed setting.
Dr Wilhelm Sandmann (Dusseldorf, Germany). I think this
was a very interesting analysis and probably gives some good
thoughts for the future.
Almost 20 years ago when we presented in Europe our expe-
rience with carotid endarterectomy with only Doppler examina-
tion, Dr Anthony Imparato, who was an invited speaker to this
meeting in Bern, Switzerland, criticized at that time that if we
would continue to perform this operation without angiography we
would be very irresponsible. Today I have the impression that even
in the United States many more vascular surgeons do not use
arteriography, but how does arteriography or only noninvasive
examination have influence on your calculations? Did you calculate
for any carotid endarterectomy the costs of arteriography as well,
or could this be subtracted because then CEA would be much
cheaper?
Dr Kilaru. That is an excellent point. In our analyses, most of
these endarterectomies were done with preoperative Doppler ex-
amination only. We found more than actually just that cost. The
long-term costs were the ones that had the most significant impact
on the model (ie, the major stroke rate). I agree that if these are
done only under Doppler, this is probably a way towards endarter-
ectomy.
Dr Gerald M. Baur (Boise, Idaho). Can you tell us whether
the costs that you are talking about in this paper are true costs,
hospital costs, or are they charges? One is real, one is artificial.
Dr Kilaru. That is a very important point. And we specifically
use only cost, because our charges vary from hospital to hospital
and they may vary within the hospital itself. So, this was specifically
cost only and not charges.
Dr Frank B. Pomposelli (Boston, Mass). Your control
group was comprised of data obtained from the outcome of carotid
endarterectomy at New York Hospital, which is a center of excel-
lence for treatment of vascular disease. What happens if you used
the data comparable with the outcomes from the study from
Cincinnati that Tom Brott reported some years ago where the
average stroke rate for carotid surgery was 10%? Other studies have
similarly shown that what happens in large centers with large
experiences does not necessarily reflect what is happening around
the country.
Dr Kilaru. That is an excellent point. We tested this in
sensitivity analysis whereby we decreased the CAS rates that we
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obtained from the literature to the stroke rates that are found in
our institution and did not find any difference in our conclusion.
However, if there is a single center that performs both these
procedures and if, in fact, the stroke rates associated with angio-
plasty and stenting are much better in that institution, most
certainly angioplasty and stenting should be performed. I think at
this time frame, since CAS is a more expensive procedure, it has to
have lower stroke rates for it to be cost effective.
Dr James C. Stanley (Ann Arbor, Mich). Most healthcare
analysts consider an operative intervention or medical-drug ther-
apy to be cost effective when the expense does not exceed $50,000
a year. You are not too far from that with carotid angioplasty and
stenting. Although your figures may favor carotid endarterectomy,
some practitioners and providers may view the cost of carotid
angioplasty and stenting as a reasonable expense to justify the
procedure. What is your perspective on the customary cost-effec-
tive break point?
Dr Kilaru. The clear cutoff point whereby a procedure is cost
effective versus not cost effective is not spelled out in stone. It is
anywhere between $50,000 to $60,000. We found that the only
way, with the present rates that we used in our data, that angio-
plasty and stenting would have a cost-effective ratio around
$68,000, provided that the stroke rates and everything were equiv-
alent to endarterectomy.
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